Can a vagus nerve stimulator (VNS) cause bradycardia?

Can Vagal Nerve Stimulator Cause Bradycardia?

Yes, vagus nerve stimulators can cause bradycardia, but this occurs primarily at higher stimulation intensities than those typically used in clinical epilepsy treatment, and the risk varies by indication and stimulation parameters.

Mechanism and Fiber Activation

VNS-induced bradycardia is mediated by activation of small-diameter myelinated B-fibers in the vagus nerve, which requires approximately 10-fold higher stimulation amplitude compared to the larger A-fibers that cause laryngeal side effects like cough and voice changes 1. This creates a therapeutic window where clinicians can achieve neurological benefits without necessarily inducing cardiac effects.

Clinical Context by Indication

For Epilepsy Treatment

In standard epilepsy applications, bradycardia is uncommon at typical therapeutic settings. Recent intraoperative data demonstrates that:

• The median stimulation amplitude to cause a 10% decrease in heart rate was 13.39 mA at 50 μs pulse width and 3.53 mA at 250 μs pulse width 2
• These bradycardia thresholds were approximately 6-63 times higher than the thresholds causing laryngeal muscle activation
• Clinician-selected therapeutic amplitudes for epilepsy were consistently lower than the thresholds required to produce bradycardia 2
• Bradycardia thresholds were two times higher than standard therapeutic settings 2

For Heart Failure Treatment

Paradoxically, in heart failure trials where bradycardia was actually desired as a therapeutic biomarker, multiple studies failed to achieve significant heart rate reduction despite using maximum tolerable stimulation amplitudes:

• The CardioFit Pilot showed no significant reduction in heart rate at 6 months despite stimulation at 1.42 ± 0.80 mA 1
• The ANTHEM-HF trial similarly showed no decrease in heart rate from baseline despite using 1.7-2.2 mA 1

This suggests that achieving clinically significant bradycardia in humans is difficult even when intentionally pursued.

Documented Cardiac Complications

While rare, serious bradyarrhythmias have been reported:

• Intraoperative risk: Direct manipulation of the cervical vagus nerve during implantation can elicit bradycardia, hypotension, and rarely asystole 3
• Delayed onset: A case report documented second-degree Mobitz type-II AV block occurring 7 years after VNS placement, which resolved after device deactivation 4
• New-onset syncope: Literature review of 22 patients with VNS-associated arrhythmia found that new syncopal events following VNS placement were significantly associated with cardiac arrhythmia (p < 0.001) 5

Critical Clinical Pitfall

The most important caveat is that new syncopal events after VNS implantation are often misattributed to worsening epilepsy rather than cardiac arrhythmia 5. Most cases of VNS-induced syncope were initially treated as breakthrough seizures with antiepileptic drug adjustments rather than being recognized as cardiac events. This represents a dangerous diagnostic error.

Monitoring Recommendations

During routine use, most patients experience only modest heart rate effects:

• Small but consistent decreases in heart rate occur during VNS episodes in 8 of 10 patients 6
• These effects occur during both rest and exercise 6
• The magnitude varies between patients but is not necessarily related to subjective side effect intensity 6

Practical Algorithm

1. Pre-implantation: Baseline cardiac evaluation, particularly in patients with pre-existing conduction abnormalities
2. Intraoperative: Anticipate potential bradycardia/asystole during nerve manipulation; have atropine/pacing readily available 3
3. Post-implantation monitoring: Any new syncopal events should prompt cardiac evaluation (loop recorder, Holter monitoring) rather than automatic assumption of seizure worsening 5
4. Device interrogation: If bradyarrhythmia is confirmed, device deactivation typically resolves the conduction abnormalities 4

The evidence indicates that while VNS can cause bradycardia through B-fiber activation, standard epilepsy treatment parameters are typically below the threshold required for significant cardiac effects, making clinically significant bradycardia uncommon but not impossible—particularly with delayed onset or parameter adjustments.